Focal adhesion kinase is overexpressed in thymic epithelial tumors and may serve as an independent prognostic biomarker

Li,Meng; Hou,Feng; Zhao,Jie; Zhang,Tianqiang; Li,Dongfei; Wu,Wensi; Liu,Xiaotong; Xu,Linhao

doi:10.3892/ol.2017.7676

Focal adhesion kinase is overexpressed in thymic epithelial tumors and may serve as an independent prognostic biomarker

Authors:
- Meng Li
- Feng Hou
- Jie Zhao
- Tianqiang Zhang
- Dongfei Li
- Wensi Wu
- Xiaotong Liu
- Linhao Xu
View Affiliations

Affiliations: Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China, Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China, Department of Cardiothoracic Surgery, The Municipal Hospital of Zaozhuang, Zaozhuang, Shandong 277100, P.R. China
Published online on: December 21, 2017 https://doi.org/10.3892/ol.2017.7676
Pages: 3001-3007
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Focal adhesion kinase (FAK) has long been considered to be a key regulator of growth factor receptor‑ and integrin‑mediated signals, with pivotal roles in tumor cells through its kinase activity and scaffolding function. Increased FAK expression and activity has been observed in tumors of various origins and is often associated with a poor prognosis. However, there have been no studies on the aberrant expression of FAK in thymic epithelial tumors to date. The aim of the present study was to evaluate FAK expression in thymic epithelial tumors and to explore the prognostic significance of FAK. FAK expression was investigated in 100 formalin‑fixed, paraffin‑embedded human thymic epithelial tumor (TET) specimens using immunohistochemical analysis with FAK‑specific monoclonal antibody 4.47, and the associations between FAK expression and clinicopathological parameters (including sex, age, tumor size, myasthenia gravis, World Health Organization classification and Masaoka‑Koga stage) were analyzed. FAK was significantly overexpressed in TETs compared with in normal thymus tissues (P<0.001). Additionally, FAK overexpression was significantly associated with advanced tumor stages (stages III or IV; P<0.001) and highly aggressive TET subtypes (type B2 and B3 thymomas and thymic carcinomas; P<0.001). Furthermore, FAK overexpression was significantly associated with a worse 10‑year overall survival, as determined by univariate analysis (P<0.001). Multivariate analysis revealed that FAK overexpression was an independent prognostic factor for patients with TETs (P=0.034). The results of the present study suggest that FAK serves an important role in the tumorigenesis and progression of TETs. Therefore, FAK may serve as a prognostic biomarker and is a potential therapeutic target for the treatment of TETs.

View Figures

View References

1	Masaoka A, Monden Y, Nakahara K and Tanioka T: Follow-up study of thymomas with special reference to their clinical stages. Cancer. 48:2485–2492. 1981. View Article : Google Scholar : PubMed/NCBI
2	Chen G, Marx A, Chen WH, Yong J, Puppe B, Stroebel P and Mueller-Hermelink HK: New WHO histologic classification predicts prognosis of thymic epithelial tumors: A clinicopathologic study of 200 thymoma cases from China. Cancer. 95:420–429. 2002. View Article : Google Scholar : PubMed/NCBI
3	Venuta F, Anile M, Diso D, Vitolo D, Rendina EA, De Giacomo T, Francioni F and Coloni GF: Thymoma and thymic carcinoma. Eur J Cardiothoracic Surg. 37:13–25. 2010. View Article : Google Scholar
4	de Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ and Groen HJ: Thymic epithelial tumours: A population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer. 44:123–130. 2008. View Article : Google Scholar : PubMed/NCBI
5	Wright CD: Management of thymomas. Crit Rev Oncol Hematol. 65:109–120. 2008. View Article : Google Scholar : PubMed/NCBI
6	Marx A, Chan JK, Coindre JM, Detterbeck F, Girard N, Harris NL, Jaffe ES, Kurrer MO, Marom EM, Moreira AL, et al: The 2015 World Health Organization Classification of tumors of the thymus: Continuity and changes. J Thorac Oncol. 10:1383–1395. 2015. View Article : Google Scholar : PubMed/NCBI
7	Gamboa EO, Sawhney V, Lanoy RS, Haller NA, Powell AT and Hazra SV: Widespread metastases after resection of noninvasive thymoma. J Clin Oncol. 26:1752–1755. 2008. View Article : Google Scholar : PubMed/NCBI
8	Jain RK, Mehta RJ, Henley JD, Kesler KA, Loehrer PJ and Badve S: WHO types A and AB thymomas: Not always benign. Mod Pathol. 23:1641–1649. 2010. View Article : Google Scholar : PubMed/NCBI
9	Okumura M, Shiono H, Inoue M, Tanaka H, Yoon HE, Nakagawa K, Matsumura A, Ohta M, Iuchi K and Matsuda H: Outcome of surgical treatment for recurrent thymic epithelial tumors with reference to world health organization histologic classification system. J Surg Oncol. 95:40–44. 2007. View Article : Google Scholar : PubMed/NCBI
10	Detterbeck FC, Nicholson AG, Kondo K, Van Schil PV and Moran C: The Masaoka-Koga stage classification for thymic malignancies: Clarification and definition of Terms. J Thorac Oncol. 6(7 Suppl 3): S1710–S1716. 2011. View Article : Google Scholar : PubMed/NCBI
11	Ogawa K, Toita T, Uno T, Fuwa N, Kakinohana Y, Kamata M, Koja K, Kinjo T, Adachi G and Murayama S: Treatment and prognosis of thymic carcinoma: A retrospective analysis of 40 cases. Cancer. 94:3115–3119. 2002. View Article : Google Scholar : PubMed/NCBI
12	Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ, Lee S, Ling A, Spittler AJ, Carter CA, et al: Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: An open-label phase 2 trial. Lancet Oncol. 16:177–186. 2015. View Article : Google Scholar : PubMed/NCBI
13	Liotta LA and Stetler-Stevenson WG: Tumor invasion and metastasis: An imbalance of positive and negative regulation. Cancer Res. 51 Suppl 18:5054S–5059S. 1991.PubMed/NCBI
14	Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB and Parsons JT: pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci USA. 89:pp. 5192–5196. 1992; View Article : Google Scholar : PubMed/NCBI
15	Hanks SK, Calalb MB, Harper MC and Patel SK: Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. Proc Natl Acad Sci USA. 89:pp. 8487–8491. 1992; View Article : Google Scholar : PubMed/NCBI
16	Lee BY, Timpson P, Horvath LG and Daly RJ: FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 146:132–149. 2015. View Article : Google Scholar : PubMed/NCBI
17	Mitra SK, Hanson DA and Schlaepfer DD: Focal adhesion kinase: In command and control of cell motility. Nat Rev Mol Cell Biol. 6:56–68. 2005. View Article : Google Scholar : PubMed/NCBI
18	Dwyer SF, Gao L and Gelman IH: Identification of novel focal adhesion kinase substrates: Role for FAK in NFκB signaling. Int J Biol Sci. 11:404–410. 2015. View Article : Google Scholar : PubMed/NCBI
19	McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG and Frame MC: The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer. 5:505–515. 2005. View Article : Google Scholar : PubMed/NCBI
20	Sulzmaier FJ, Jean C and Schlaepfer DD: FAK in cancer: Mechanistic findings and clinical applications. Nat Rev Cancer. 14:598–610. 2014. View Article : Google Scholar : PubMed/NCBI
21	Cance WG, Harris JE, Iacocca MV, Roche E, Yang X, Chang J, Simkins S and Xu L: Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: Correlation with preinvasive and invasive phenotypes. Clin Cancer Res. 6:2417–2423. 2000.PubMed/NCBI
22	Itoh S, Maeda T, Shimada M, Aishima S, Shirabe K, Tanaka S and Maehara Y: Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma. Clin Cancer Res. 10:2812–2817. 2004. View Article : Google Scholar : PubMed/NCBI
23	Lark AL, Livasy CA, Calvo B, Caskey L, Moore DT, Yang X and Cance WG: Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: Immunohistochemistry and real-time PCR analyses. Clin Cancer Res. 9:215–222. 2003.PubMed/NCBI
24	Owens LV, Xu L, Craven RJ, Dent GA, Weiner TM, Kornberg L, Liu ET and Cance WG: Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res. 55:2752–2755. 1995.PubMed/NCBI
25	Beierle EA, Massoll NA, Hartwich J, Kurenova EV, Golubovskaya VM, Cance WG, McGrady P and London WB: Focal adhesion kinase expression in human neuroblastoma: Immunohistochemical and real-time PCR analyses. Clin Cancer Res. 14:3299–3305. 2008. View Article : Google Scholar : PubMed/NCBI
26	Canel M, Secades P, Rodrigo JP, Cabanillas R, Herrero A, Suarez C and Chiara MD: Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number. Clin Cancer Res. 12:3272–3279. 2006. View Article : Google Scholar : PubMed/NCBI
27	Schneider GB, Kurago Z, Zaharias R, Gruman LM, Schaller MD and Hendrix MJ: Elevated focal adhesion kinase expression facilitates oral tumor cell invasion. Cancer. 95:2508–2515. 2002. View Article : Google Scholar : PubMed/NCBI
28	Lai IR, Chu PY, Lin HS, Liou JY, Jan YJ, Lee JC and Shen TL: Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance. Am J Pathol. 177:1629–1637. 2010. View Article : Google Scholar : PubMed/NCBI
29	Recher C, Ysebaert L, Beyne-Rauzy O, Mansat-De Mas V, Ruidavets JB, Cariven P, Demur C, Payrastre B, Laurent G and Racaud-Sultan C: Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res. 64:3191–3197. 2004. View Article : Google Scholar : PubMed/NCBI
30	Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD and Hendrix MJ: Biological significance of focal adhesion kinase in ovarian cancer: Role in migration and invasion. Am J Pathol. 165:1087–1095. 2004. View Article : Google Scholar : PubMed/NCBI
31	Fujii T, Koshikawa K, Nomoto S, Okochi O, Kaneko T, Inoue S, Yatabe Y, Takeda S and Nakao A: Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor. J Hepatol. 41:104–111. 2004. View Article : Google Scholar : PubMed/NCBI
32	Miyazaki T, Kato H, Nakajima M, Sohda M, Fukai Y, Masuda N, Manda R, Fukuchi M, Tsukada K and Kuwano H: FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer. 89:140–145. 2003. View Article : Google Scholar : PubMed/NCBI
33	Golubovskaya VM: Targeting FAK in human cancer: From finding to first clinical trials. Front Biosci (Landmark Ed). 19:687–706. 2014. View Article : Google Scholar : PubMed/NCBI
34	Ocak S, Chen H, Callison C, Gonzalez AL and Massion PP: Expression of focal adhesion kinase in small-cell lung carcinoma. Cancer. 118:1293–1301. 2012. View Article : Google Scholar : PubMed/NCBI
35	Ji HF, Pang D, Fu SB, Jin Y, Yao L, Qi JP and Bai J: Overexpression of focal adhesion kinase correlates with increased lymph node metastasis and poor prognosis in non-small-cell lung cancer. J Cancer Res Clin Oncol. 139:429–435. 2013. View Article : Google Scholar : PubMed/NCBI